Specifically, V9302 has been shown to promote cancer cell autophagy, further enhance anti-tumor immunity by regulating ROS accumulation, decrease the expression of the T-cell co-suppressor molecule B7H3, and promote the production of GZMB by CD8 T cells [109]
DPP-4i was selected as the active comparator given its documented cardiovascular neutrality, whereas sodium-glucose cotransporter-2 inhibitors were not used as a comparator due to their established cardiovascular benefits
Armed with this genetic context, you and your provider can have a more informed discussion about whether standard-dose semaglutide, microdose GLP-1 protocols, tirzepatide, or dual-compound approaches (like GLP-Squared) may be worth exploring based on your individual risk profile and side effect tolerability
Whilst there is no absolute contraindication to consuming sweets during Wegovy therapy, understanding the relationship between sugar intake, medication effectiveness, and tolerability is essential